Synlogic presents data demonstrating activity of a solid oral formulation of synb1618 at american college of medical genetics (acmg) annual meeting

Cambridge, mass., april 13, 2021 synlogic, inc. (nasdaq: sybx), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data from the phase 1 study of synb1618 for the treatment of phenylketonuria (pku) during the american college of medical genetics (acmg) annual meeting, being held virtually april 13-16, 2021.
SYBX Ratings Summary
SYBX Quant Ranking